Introducing Signant Health
CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, launched as Signant Health - uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies, and Endpoint Quality into a patient-centric suite.
“The best technology in clinical research succeeds in the background,” said Mike Nolte, CEO of Signant Health. “We work to be expert, with proven solutions and scientific support that simplify research for patients, sponsors and CROs. I’m humbled to be a part of our customers’ important work, proud of the Signant Health team and excited to continue to innovate along every step of the patient journey.”
Signant Health combines a comprehensive, united suite of proven technologies with developers, project managers, data analysts, scientists and clinicians.
“The new Signant brand reflects our desire to help separate signal from noise at the intersection of science and technology and to never forget that our customers’ significant work matters locally and globally,” added Nolte. ”In 2018, CRF Health and Bracket brought together industry-leading technology and analytics solutions, renowned executive and scientific leaders, and 20 years of experience delivering exemplary service to life science companies worldwide. The birth of Signant Health marks the next phase in our journey and unlocks extraordinary opportunities to improve the patient’s journey as well.”
To learn more about Signant Health’s solutions, visit www.signanthealth.com
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
